Table 2. Risk of long-term dialysis and death among patients with advanced CKD comparing dipyridamole users vs. nonusers.
| Before Matching | After Matching | ||||||
|---|---|---|---|---|---|---|---|
| N of event | Incidence rate (100 person- years) | Crude HR (95% CI) | Adjusted HR (95% CI) | N of event | Incidence rate (100 person- years) | Adjusted HR (95% CI) | |
| Long-term dialysis | |||||||
| Dipyridamole nonuser | 14,463 | 74.26 | 1.0 (reference) | 1.0 (reference) | 10,480 | 72.48 | 1.0 (reference) |
| Dipyridamole user | 5,689 | 69.35 | 0.94 (0.91–0.97)* | 0.97 (0.94–1.00)* | 5,531 | 69.73 | 0.96 (0.93–0.99)* |
| < 140 DDD | 2,768 | 72.49 | 0.98 (0.94–1.02) | 1.02 (0.98–1.06) | 2,695 | 73.18 | 1.02 (0.98–1.06) |
| ≥ 140 DDD | 2,921 | 66.61 | 0.91 (0.87–0.95)* | 0.92 (0.88–0.96)* | 2,836 | 66.74 | 0.91 (0.87–0.95)* |
| < 75 mg/day | 2,617 | 72.90 | 0.99 (0.95–1.03) | 1.02 (0.98–1.07) | 2,546 | 73.66 | 1.03 (0.98–1.07) |
| ≥ 75 mg/day | 3,072 | 66.58 | 0.91 (0.87–0.94)* | 0.92 (0.89–0.96)* | 2,985 | 66.70 | 0.91 (0.88–0.95)* |
| Death | |||||||
| Dipyridamole nonuser | 4,116 | 21.13 | 1.0 (reference) | 1.0 (reference) | 3,087 | 21.35 | 1.0 (reference) |
| Dipyridamole user | 1,581 | 19.27 | 0.91 (0.86–0.96)* | 0.90 (0.85–0.95)* | 1,536 | 19.37 | 0.91 (0.85–0.97)* |
| < 140 DDD | 828 | 21.69 | 1.02 (0.95–1.10) | 0.95 (0.88–1.02) | 800 | 21.72 | 0.95 (0.88–1.03) |
| ≥ 140 DDD | 753 | 17.17 | 0.81 (0.75–0.87)* | 0.85 (0.79–0.92)* | 736 | 17.32 | 0.86 (0.80–0.94)* |
| < 75 mg/day | 781 | 21.76 | 1.03 (0.95–1.11) | 0.94 (0.87–1.02) | 754 | 21.81 | 0.95 (0.87–1.03) |
| ≥ 75 mg/day | 800 | 17.34 | 0.82 (0.76–0.88)* | 0.86 (0.80–0.93)* | 782 | 17.47 | 0.87 (0.81–0.95)* |
CI = confidence interval. CKD = chronic kidney disease. DDD = defined daily doses. HR = hazard ratio
A multivariate analysis was adjusted for all variables listed in Table 1.
*P < 0.05 compared with dipyridamole nonusers